Capricor Therapeutics reported $58.33M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Bioline Rx BLRX:US $ 11.45M 1.54M
Bluebird Bio BLUE:US $ 106.26M 54.9M
Capricor Therapeutics CAPR:US $ 58.33M 23.45M
Cytokinetics CYTK:US $ 115.42M 2.76M
Cytori Therapeutics CYTX:US $ 21.24M 2.84M
Geron GERN:US $ 31.32M 3.55M
Johnson & Johnson JNJ:US $ 1579M 322M
Newlink Genetics NLNK:US $ 86.76M 8.05M
Prothena PRTA:US $ 542.99M 36.1M
Ptc Therapeutics PTCT:US $ 144.18M 45.54M
Sarepta Therapeutics SRPT:US $ 1233.88M 881.99M
Vascular Biogenics VBLT:US 13.25M 8.73M
Vital Therapies VTL:US $ 95.71M 8.85M